Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer’s disease: emerging roles in astrocyte activation and pathological signaling
- 1Shaanxi Key Laboratory of Brain Disorders, Institute of Basic and Translational Medicine, School of Life Science and Engineering, Xi’an Medical University
- 2State Key Laboratory of Cancer Biology and Department of Physiology and Pathophysiology, School of Basic Medical Science, Air Force Medical University
- 3Department of Cardiac Function, Affiliated Hospital of Yangzhou University; School of Nursing, Faculty of Medicine & Key Laboratory of the Jiangsu Higher Education Institutions for Integrated Traditional Chinese and Western Medicine in Senile Diseases Control, Yangzhou University
Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau pathology, and persistent neuroinflammation. Although therapeutic strategies targeting Aβ and Tau have significantly advanced our understanding of AD pathogenesis, growing attention has been directed toward the role of immune dysregulation in AD progression, highlighting the need to identify immune regulators that contribute to AD-associated pathological mechanisms. Interferon-induced transmembrane protein 3 (IFITM3), an interferon-responsive membrane protein involved in innate immune responses, has recently emerged as a potential regulator of AD-associated pathological processes. Experimental and transcriptomic studies suggest that IFITM3 modulates γ-secretase activity, amyloidogenic processing, inflammatory activation, and membrane trafficking pathways. Notably, IFITM3 is enriched in reactive astrocyte populations, raising the possibility that astrocytic IFITM3 contributes to the regulation of interferon-associated glial responses and neuroinflammatory signaling. In this review, we summarize current evidence regarding the role of IFITM3 in AD, focusing on astrocyte-associated mechanisms, including inflammatory regulation, endo-lysosomal dysfunction, and extracellular vesicle-mediated communication. We further discuss IFITM3-related signaling across astrocytes, neurons, microglia, vascular cells, and peripheral immune compartments, as well as emerging therapeutic approaches targeting IFITM3-associated pathways. Collectively, current evidence suggests that IFITM3 may serve as a potential regulatory interface connecting interferon activation, neuroimmune dysregulation, amyloid metabolism, and neuroinflammatory signaling, providing new perspectives on astrocyte-mediated mechanisms and therapeutic intervention in AD.
Related
- Interferon-induced transmembrane proteins in cancer and virus biology: a membrane perspective
- BAP1 as a novel regulator of type I interferon signaling through transcriptional control of key response machinery components
- ISG15 Is a Key Multidirectional Regulator of Cytosolic RNA- and DNA-Sensing Pathways and Type I Interferon Feedback Loops
- Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis
- Interferon-Induced Protein 6 (IFI6): Biological Functions, Molecular Mechanisms and Pathological Roles in Human Diseases
BibTeX
@article{zhang2026interferoninduced,
title = {{Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer’s disease: emerging roles in astrocyte activation and pathological signaling}},
author = {Tianying Zhang and Jiangtao Huang and Haoping Wang and Jing Li and Xiaojuan Han and Yuan Yuan},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1978082},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978082/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Interferon-induced transmembrane protein 3 (IFITM3) as a neuroimmune regulator in Alzheimer’s disease: emerging roles in astrocyte activation and pathological signaling
AU - Tianying Zhang
AU - Jiangtao Huang
AU - Haoping Wang
AU - Jing Li
AU - Xiaojuan Han
AU - Yuan Yuan
PY - 2026
DA - 2026/11/03
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1978082
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978082/full
AB - Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau pathology, and persistent neuroinflammation. Although therapeutic strategies targeting Aβ and Tau have significantly advanced our understanding of AD pathogenesis, growing attention has been directed toward the role of immune dysregulation in AD progression, highlighting the need to identify immune regulators that contribute to AD-associated pathological mechanisms. Interferon-induced transmembrane protein 3 (IFITM3), an interferon-responsive membrane protein involved in innate immune responses, has recently emerged as a potential regulator of AD-associated pathological processes. Experimental and transcriptomic studies suggest that IFITM3 modulates γ-secretase activity, amyloidogenic processing, inflammatory activation, and membrane trafficking pathways. Notably, IFITM3 is enriched in reactive astrocyte populations, raising the possibility that astrocytic IFITM3 contributes to the regulation of interferon-associated glial responses and neuroinflammatory signaling. In this review, we summarize current evidence regarding the role of IFITM3 in AD, focusing on astrocyte-associated mechanisms, including inflammatory regulation, endo-lysosomal dysfunction, and extracellular vesicle-mediated communication. We further discuss IFITM3-related signaling across astrocytes, neurons, microglia, vascular cells, and peripheral immune compartments, as well as emerging therapeutic approaches targeting IFITM3-associated pathways. Collectively, current evidence suggests that IFITM3 may serve as a potential regulatory interface connecting interferon activation, neuroimmune dysregulation, amyloid metabolism, and neuroinflammatory signaling, providing new perspectives on astrocyte-mediated mechanisms and therapeutic intervention in AD.
SN - 1664-3224
ER -